How many courses of treatment does Seleniso usually take?

Selinexor (Selinexor) is a targeted therapy commonly used to treat relapsed and refractory multiple myeloma and other types of hematological tumors. The treatment plan is based on the patient's specific situation, including disease type, patient tolerance, treatment response and other factors. During the treatment process, the drug use cycle and course of treatment will vary depending on individual differences, and the doctor will make adjustments based on the patient's clinical performance.

For people with multiple myeloma, seleniso is often given in combination with other chemotherapy drugs, such as fludarabine or lenalidomide. Standard treatment typically involves oral selinesol twice weekly for 28 days. After the patient has been on treatment for two to three months, the doctor will evaluate whether to continue treatment based on the response of the disease. Depending on the patient's specific condition and treatment response, some patients may require long-term maintenance treatment, while others may stop taking medication after a certain course of treatment.

During the treatment process, the doctor will adjust the dose or course of selinesol based on the patient’s response. For example, early in treatment, doctors will monitor patients for side effects and effectiveness to determine whether medication dosage needs to be adjusted. If the patient tolerates the drug poorly, the dose may need to be reduced or treatment intervals extended. For patients with better disease response, the current treatment plan may be maintained or even extended.

For some patients who respond well to initial treatment, selinesol may be continued as maintenance therapy. Maintenance treatment aims to delay disease recurrence and improve the patient's quality of life. Depending on response to treatment, some patients may continue to take selinesol until new disease progression occurs or treatment effects diminish. Maintenance therapy is usually given at lower doses to reduce side effects and improve long-term tolerability. The specific treatment plan and course of treatment need to be decided by the patient's attending physician based on the patient's specific situation.

Selinesol treatment courses are often individualized and adjusted according to the patient's different conditions, drug resistance and side effects. In addition to multiple myeloma, selinexol's treatment options will also be different when treating other types of cancer (such as acute myeloid leukemia, lymphoma, etc.). Therefore, patients need to work closely with their doctors to conduct regular examinations, evaluate the efficacy, and adjust the course of treatment as needed.

xa0

Reference materials:

National Medical Products Administration (NMPA) official website. Seleniso Approval Information:https://www.nmpa.gov.cn